We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| IS Pharma | ISPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 87.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 87.00 | 87.00 |
| Top Posts |
|---|
Posted at 16/8/2011 13:18 by danielmiller1 Been out of it for a while chaps what happened to ISPH WAS IT A GOOD DEAL FOR SHAREHOLDERS? |
Posted at 03/5/2011 16:20 by red ninja Looks like merger will conclude 23/5/11 (end ISPH) listingDirector buying SPH at 36p Topped up 5000 ISPH also, seem good value against SPH sp |
Posted at 07/4/2011 15:56 by red ninja After merger deals it always takes time to settle down, but for SPH holders it seems an easy move to sell SPH and buy ISPH until the differential disappears .. |
Posted at 23/2/2011 08:28 by philo124 Worth 99p at the moment; looking at ISPH eps forecasts, merger should fail. |
Posted at 06/12/2010 16:57 by gogoneko Having seen some disastrous investment decisions elsewhere by Blackrock I can't say their choices are faultless, but hopefully here they won't have any cause to regret their ISPH investment. Nevertheless it's nice to have an expanding institutional investor base from purchases at reasonably fair prices. |
Posted at 06/12/2010 16:28 by red ninja Blackrock love us too. How things have changed for ISPH... |
Posted at 06/10/2010 17:31 by tackems If it is a deal lined up then it will probably be one of the directors selling one of their own companies into ISPH as they have already done in the past!! |
Posted at 06/10/2010 08:23 by clogue Just had a look at Abingworth and they look to be a very, very impressive outfit.If Abingworth are prepared to invest at a premium ( after going over the company in great detail) them things must look very good at ISPH. The company now has over £7m cash so I wonder if they have another deal lined up. If they intend to buy I take it that Abingworth know about it. |
Posted at 25/6/2010 16:31 by red ninja Market volatile, ISPH illiquid and volatile share.Provides good buying opportunities for the patient .... |
Posted at 04/6/2010 00:08 by gogoneko There's also the issue of transparency.Why didn't the ISPH directors inform all investors of the failed Lucassin NDA submission when it was known to Orphan back in November? In December they wrote : "In the US, the FDA has issued a Complete Response Letter for Lucassin (US tradename for Variquel). Our US partners plan to meet with the FDA in the coming months.". Why not provide an explanation, or at least why not inform all investors so that everyone could have offloaded in anticipation of a 30-40% slump in the shares price! Also there was no update announced on the recent agreement between Orphan and Ikaria regaring Ikaria's takeover of the NDA process - have further problems arisen? Considering the royalty revenues from Lucassin form part of ISPH's projected revenues, investors should be updated on progress, or lack of it, as soon as it becomes available. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
